All In Biotech

Drug Trial Radar · NCT03778554

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction (DANBLOCK)

Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 2,760 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,760

Planned (sponsor's estimate)

Start

Dec 17, 2018

Primary completion

Apr 1, 2025

Study completion Dec 10, 2035

Sponsor

Lead sponsor
Bispebjerg HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Amager Hospital; University Hospital Bispebjerg and Frederiksberg; Bornholm Hospital; Gentofte Hospital; Glostrup University Hospital, Copenhagen; Herlev Hospital; Hvidovre University Hospital; Nordsjaellands Hospital; Holbaek Hospital; Nykoebing Hospital; Naestved Hospital; Zealand University Hospital; Slagelse Hospital; Odense University Hospital; Svendborg Hospital; Sydvestjysk Sygehus; Hospital of Southern Jutland; Sygehus Lillebaelt (Vejle and Kolding); Aarhus University Hospital; Hospitalsenheden Midt; Hospitalsenheden Vest; Regionshospitalet Horsens; Silkeborg Sygehus; Aalborg University Hospital
First posted
Dec 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine whether long-term treatment with oral betablocker therapy after myocardial infarction in patient with no heart failure reduces the composite outcome of recurrent MI, all-cause mortality, revascularisation with percutaneous coronary intervention or coronary artery bypass graft, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.

Conditions

  • Acute Myocardial Infarction
  • Non-ST Elevation Myocardial Infarction (nSTEMI)
  • ST Elevation Myocardial Infarction

Interventions

  • Metoprolol SuccinateDrug

    Eligible patients randomized to receive long-term therapy with oral beta-blockade

  • BisoprololDrug

    Eligible patients randomized to receive long-term therapy with oral beta-blockade

  • CarvedilolDrug

    Eligible patients randomized to receive long-term therapy with oral beta-blockade

  • NebivololDrug

    Eligible patients randomized to receive long-term therapy with oral beta-blockade

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A composite of all-cause mortality, recurrent MI, revascularisation with PCI or CABG, ischemic stroke, incident heart failure, or malignant ventricular arrhythmia including resuscitated cardiac arrest of cardiac origin.Time frame: Estimated follow-up min 6 months - max 6.25 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bispebjerg Hospital, Dept. of Cardiology Y builing 67, 1.floor, Bispebjerg Bakke 23

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.